[go: up one dir, main page]

NI201700066A - Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson - Google Patents

Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson

Info

Publication number
NI201700066A
NI201700066A NI201700066A NI201700066A NI201700066A NI 201700066 A NI201700066 A NI 201700066A NI 201700066 A NI201700066 A NI 201700066A NI 201700066 A NI201700066 A NI 201700066A NI 201700066 A NI201700066 A NI 201700066A
Authority
NI
Nicaragua
Prior art keywords
parkinson
treatment
adhd
antagonists
disease
Prior art date
Application number
NI201700066A
Other languages
English (en)
Inventor
Frydelund Larsen Lone
Areberg Johan
Breysse Nathalie
Chandrasena Gamini
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of NI201700066A publication Critical patent/NI201700066A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a dosis específicas de un antagonista de A2A para utilizarlo como un medicamento y, en particular, que sean útiles para el tratamiento de enfermedades de Parkinson y del trastorno por déficit de atención con hiperactividad.
NI201700066A 2014-12-03 2017-06-01 Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson NI201700066A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03

Publications (1)

Publication Number Publication Date
NI201700066A true NI201700066A (es) 2018-01-04

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201700066A NI201700066A (es) 2014-12-03 2017-06-01 Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson

Country Status (25)

Country Link
US (2) US20160158211A1 (es)
EP (1) EP3226863A1 (es)
JP (1) JP2017536400A (es)
KR (1) KR20170090430A (es)
CN (1) CN106999480A (es)
AU (1) AU2015357197A1 (es)
BR (1) BR112017011777A2 (es)
CA (1) CA2966582A1 (es)
CL (1) CL2017001407A1 (es)
CO (1) CO2017004785A2 (es)
CR (1) CR20170221A (es)
DO (1) DOP2017000121A (es)
EA (1) EA201790973A1 (es)
EC (1) ECSP17030050A (es)
IL (1) IL252355A0 (es)
MA (1) MA41090A (es)
MX (1) MX2017007027A (es)
NI (1) NI201700066A (es)
PE (1) PE20170926A1 (es)
PH (1) PH12017500923A1 (es)
SG (1) SG11201704370XA (es)
SV (1) SV2017005441A (es)
TN (1) TN2017000174A1 (es)
TW (1) TW201632186A (es)
WO (1) WO2016087429A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279829B2 (en) 2018-07-05 2025-05-01 Incyte Holdings Corp Fused pyrazine derivatives as A2A/A2B inhibitors
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004309279B2 (en) * 2003-12-26 2010-07-15 Kyowa Kirin Co., Ltd. Thiazole derivative
CN102105168A (zh) * 2008-07-23 2011-06-22 协和发酵麒麟株式会社 偏头痛治疗剂
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
CA2966582A1 (en) 2016-06-09
DOP2017000121A (es) 2017-07-15
MA41090A (fr) 2017-10-10
PE20170926A1 (es) 2017-07-13
SG11201704370XA (en) 2017-06-29
MX2017007027A (es) 2017-08-24
US20180125835A1 (en) 2018-05-10
KR20170090430A (ko) 2017-08-07
CN106999480A (zh) 2017-08-01
CO2017004785A2 (es) 2017-08-31
TW201632186A (zh) 2016-09-16
EA201790973A1 (ru) 2017-10-31
CL2017001407A1 (es) 2018-01-05
IL252355A0 (en) 2017-07-31
AU2015357197A1 (en) 2017-05-25
TN2017000174A1 (en) 2018-10-19
CR20170221A (es) 2017-10-05
WO2016087429A1 (en) 2016-06-09
SV2017005441A (es) 2017-08-25
JP2017536400A (ja) 2017-12-07
US20160158211A1 (en) 2016-06-09
EP3226863A1 (en) 2017-10-11
BR112017011777A2 (pt) 2018-02-20
PH12017500923A1 (en) 2017-11-20
ECSP17030050A (es) 2017-08-31

Similar Documents

Publication Publication Date Title
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
NI201700066A (es) Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
BR112017016333A2 (pt) compostos anticâncer
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
MX2016013588A (es) Complejo de tanato de sitagliptina.
PT3154597T (pt) Métodos de preparação para uma nova geração de produtos biológicos de klh seguros utilizados para o tratamento de cancro, para o desenvolvimento de de vacinas conjugadas terapêuticas e como agentes competitivos